Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Center for Prevention of Progression of Blood Cancers (CPOP)

  • Center for Prevention of Progression (CPOP) team members

  • Although many patients are diagnosed with earlier phases (also known as "precursor conditions") of blood cancers, in most cases, there are no effective, disease-modifying therapies available. This means that most patients do not receive treatment until their cancer progresses.

    Precursor hematologic conditions include early cases of chronic lymphocytic leukemia called monoclonal B cell lymphocytosis (MBL); early cases of multiple myeloma or Waldenström's Macroglobulinemia called monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma; and early cases of myelodysplastic syndrome and myeloproliferative disorders.

    In order to understand why some patients with these precursor conditions go on to develop progressive disease, while others do not show progression — and to develop better targeted therapeutic agents to prevent progression, or even eliminate the disease before it leads to symptoms — the Center for Prevention of Progression of Blood Cancers (CPOP) has been created.

    Although the last decade has seen the development of effective target therapies for patients with blood cancers, their clinical use has been hampered by drug resistance, clonal evolution, and disease progression — all of which limit the extent and duration of patients' response.

    Of note, most blood cancers — including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia — are preceded by clonal disease states that then progress into disease. However, the genomic, genetic, and epigenetic factors governing the process of progression and therapeutic resistance have not been systematically characterized.

    The Center for Prevention of Progression research initiative is focused on understanding the progression and clonal evolution of blood cancers, with an ultimate aim to develop targeted therapeutic agents that can eliminate the early clones of disease.


  • Irene Ghobrial, MD, describes the CPOP research initiative


  • Leadership

    Robert Soiffer, MD
    Irene Ghobrial, MD
    Benjamin Ebert, MD, PhD

    Research Partners

    Jennifer Brown Lab
    Benjamin Ebert Lab
    Gad Getz Lab
    Irene Ghobrial Lab
    Catherine Marinac, PhD
    Timothy Rebbeck, PhD

    Research Staff

    Hira Shrestha, MA, Senior Clinical Research Program Manager
    Brian Sheehan, Assistant Clinical Research Manager
    Meredith Bertoni, MPH, Clinical Research Coordinator II
    Elizabeth Murphy, Clinical Research Coordinator II
    Dechen Choden, Clinical Research Coordinator I
    Sophie Magidson, Clinical Research Coordinator I
    Erica Horowitz, Research Project Manager
    Maya Davis, Research Project Manager
    Lilly Riseberg, Clinical Research Coordinator I
    Jackie Perry, MPH, Data Manager
    Vidhi Patel, Research Data Specialist

    Clinical Team

    Hematology/Oncology

    Myeloma Precursor Specialists

    Irene Ghobrial, MD, MGUS, SMM
    Omar Nadeem, MD, MGUS, SMM
    Betsy O'Donnell, MD, MGUS, SMM
    Adam Sperling, MD, PhD, MGUS, SMM

    Leukemia Precursor Specialists

    Daniel DeAngelo, MD, PhD, low-risk MDS
    Lachelle D. Weeks, MD, PhD, ICUS, CHIP, CCUS, low-risk MDS

    Lymphoma Precursor Specialists

    Virginia Volpe, MD, MBL

    Genetic Risk and Prevention

    Judy Garber, MD, MPH
    Huma Rana, MD

    Cardiology

    Peter Libby, MD

    Nephrology

    Shruti Gupta, MD
    Umut Selamet, MD

    Neurology

    Christopher Doughty, MD